Release Details

TARRYTOWN, N.Y., Feb 12, 2007 (BUSINESS WIRE) -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) and sanofi-aventis are collaborating on the development of Regeneron's Vascular Endothelial Growth Factor (VEGF) Trap in oncology. On February 13, 2007, sanofi-aventis will report its 2006 annual results and review its development pipeline. As part of this review, sanofi-aventis will provide an update of the VEGF Trap clinical program. The presentation is scheduled to be webcast live beginning at 8:30 a.m. Paris Time (2:30 a.m. Eastern Time) and can be accessed through the sanofi-aventis website (www.sanofi-aventis.com) at the time of the presentation. An archived version of the presentation will be available after the live webcast on the sanofi-aventis website.

Regeneron is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic medicines for the treatment of serious medical conditions. Regeneron has therapeutic candidates for the potential treatment of cancer, eye diseases, and inflammatory diseases and has preclinical programs in other diseases and disorders.

During this webcast, sanofi-aventis will discuss historical information and include forward-looking statements about Regeneron and the VEGF Trap oncology program, which involve a number of risks and uncertainties, such as risks associated with preclinical and clinical development of our product candidates, determinations by regulatory and administrative governmental authorities which delay or restrict our ability to continue to develop or commercialize our product candidates, competing drugs that are superior to our product candidates, unanticipated expenses, the availability and cost of capital, the costs of developing, producing, and selling products, the potential for any collaboration agreement, including our agreement with sanofi-aventis, to be canceled or to terminate without any product success, risks associated with third party intellectual property, and other material risks. A more complete description of these and other material risks can be found in Regeneron's filings with the United States Securities and Exchange Commission (SEC), including its Form 10-K for the year ended December 31, 2005 and its Form 10-Q for the quarter ended September 30, 2006. Regeneron does not undertake any obligation to update publicly any forward-looking statement, whether as a result of new information, future events, or otherwise unless required by law.

Additional information about Regeneron and recent news releases are available on Regeneron's worldwide web site at www.regeneron.com

SOURCE: Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc.
Charles Poole, 914-345-7640
Vice President, Investor Relations
charles.poole@regeneron.com
or
Lauren Tortorete, 212-845-5609
Media Relations
ltortorete@biosector2.com